Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

g dirucotide

(MBP8298) for the treatment of SPMS. The trial is fully recruited

with approximately 510 patients enrolled at 68 sites across the U.S.

To date, the DSMB has conducted three reviews of the data from this

trial and has recommended it continue.

- MINDSET-01: A phase II clinical trial evaluating dirucotide (MBP8298)

for the treatment of relapsing-remitting MS (RRMS). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in six countries across Europe. The DSMB

has completed six safety reviews to date and recommended that the

trial continue as per the protocol. Completion of the double-blind

phase of the trial is expected at the end of 2008 with results

anticipated in the first quarter of 2009.

Financial Results

The consolidated net income for the three months ended September 30, 2008 was $6.3 million or $0.07 per share compared with a net loss of $10.9 million or ($0.12) per share for the three months ended September 30, 2007. The consolidated net loss for the nine months ended September 30, 2008 was $0.8 million or ($0.01) per share compared with a loss of $35.5 million or ($0.43) per share for the same period in 2007.

Revenue for the three months ended September 30, 2008 was $16.1 million compared to $nil for the same period of 2007. Revenue for the nine months ended September 30, 2008 was $40.1 million compared to $nil for the same period of 2007. The revenue is the result of recognizing a portion of the upfront payment and development milestone for the positive interim analysis related to the MAESTRO-01 clinical trial received from the licensing agreement with Lilly.

Total consolidated expenses for the three months ended September 30, 2008 were $11.8 million compared to $10.6 million for the same period of 2007. Total consolidated expenses for the nine months
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... May 16, 2013 Oven Industries, Inc. ... controllers and temperature sensors since 1964. Expertly ... in industrial control system applications. As one ... includes a generic, control loop feedback system, which helps ... used to adjust a systematic process, using a control ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 Cambridge Healthtech ... from August 19-23, 2013 at the Renaissance Waterfront Hotel ... Summit provide a close-up look at the current strategies ... ensuring bottom-line quality. Leaders in the field will ... to produce biopharmaceuticals with greater specificity and efficiency. , ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... JCA-Mauvernay Award, LAUSANNE, Switzerland, October 29 ... specialist that,focuses on serious medical conditions and ... Mano with the 2008 JCA-Mauvernay,Award for their ... oncology.,The Awards were presented during the General ...
... Proximal Anastomosis System Received 510(k) Clearance from ... Drug Administration (FDA) -, - Development Progress Triggered $1M Milestone Payment from ... - Conference Call Today at 4:30 p.m. Eastern Time -, REDWOOD ... financial results and corporate progress,for its fiscal 2009 first quarter ended September ...
... COLUMBIA, Canada, Oct. 28 InNexus,Biotechnology Inc., (OTC ... a drug development company commercializing the next,generation of ... technology, announces that Jeff Morhet, CEO and Chairman, ... on October 30, 2008., Mr. Morhet,s thirty-minute ...
Cached Biology Technology:Japanese Cancer Association and Debiopharm Honour Japanese Research 2Japanese Cancer Association and Debiopharm Honour Japanese Research 3Cardica Announces Fiscal 2009 First Quarter Financial Results 2Cardica Announces Fiscal 2009 First Quarter Financial Results 3Cardica Announces Fiscal 2009 First Quarter Financial Results 4Cardica Announces Fiscal 2009 First Quarter Financial Results 5Cardica Announces Fiscal 2009 First Quarter Financial Results 6InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2
(Date:5/16/2013)... a gene involved in neurodegenerative disease also plays a ... clock. , In a study of the common ... keeps the clock responsible for sleeping and waking on ... the fruit fly,s sleep-wake cycle is disturbed, making waking ... , The discovery is particularly interesting because mutations ...
(Date:5/16/2013)... 16, 2013 The relationship between the heritable ... not been clear. Schizophrenia is commonly associated with ... are clues that reduced IQ may be linked ... reduced cognitive ability may precede the onset of ... in healthy relatives of people diagnosed with schizophrenia. ...
(Date:5/16/2013)... with ,scissor hand-like, claws in fossil records and has ... , The 505 million year old fossil called ... a distant ancestor of lobsters and scorpions, was named ... as Edward Scissorhands - a movie about an artificial ... for hands. , Kooteninchela deppi is ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2Actor Johnny Depp immortalized in ancient fossil find 2
... EMBARGOED UNTIL 1 P.M. EST 12/20/09 -- Boston ... future genome sequencing faster and cheaper by dramatically reducing ... time-consuming and error-prone step of DNA amplification. ... online edition of Nature Nanotechnology, a team ...
... Springer as the co-publisher of its Journal of ... quarterly journal will start publication at Springer with Volume ... 2001 will be available on Springer,s electronic platform ... and Environmental Statistics publishes papers of value to ...
... , SEATTLE, Dec. 18 Pacific Biometrics, Inc. ... provider of specialized central laboratory and contract research services, today ... voted upon at the Company,s Annual Meeting on December 14, ... change in the Company,s name to "Pacific Biomarkers, Inc." ...
Cached Biology News:Boston University reseachers develop faster, cheaper DNA sequencing method 2International Biometric Society co-publishes journal with Springer 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 2Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 3Pacific Biometrics, Inc. Stockholders Approve Company Name Change to Pacific Biomarkers, Inc. 4
MpV17 transgene, murine homolog, glomerulosclerosis...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Silencer Validated and Silencer ...
Biology Products: